Stemline Therapeutics misses by $0.01, beats on revenue

• Stemline Therapeutics (NASDAQ:STML): Q1 EPS of -$0.46 misses by $0.01.
• Revenue of $0.12M (+71.4% Y/Y) beats by $0.07M.
• Press Release